NCT04852367View on ClinicalTrials.gov

PanDox: Targeted Doxorubicin in Pancreatic Tumours

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 16, 2021

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2023

Conditions
Pancreatic Ductal AdenocarcinomaPancreatic Cancer Stage IVPancreatic Cancer Non-resectablePancreatic Cancer Metastatic
Interventions
DEVICE

Focused Ultrasound

Focused ultrasound targetting the tumour at subablative powers, to facilitate drug release

DRUG

Doxorubicin

Doxorubicin infusion

DRUG

ThermoDox

ThermoDox infusion

Trial Locations (1)

OX3 7LE

Oxford University Hospitals NHS Trust, Oxford

Sponsors

Collaborators (1)

Imunon
All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

collaborator

Imunon

INDUSTRY

lead

University of Oxford

OTHER

NCT04852367 - PanDox: Targeted Doxorubicin in Pancreatic Tumours | Biotech Hunter | Biotech Hunter